HUB-AND-SPOKE BIOTECH DEVELOPMENT ENGINE POWERING EFFICEINT SMALL-SCALE MED-TECH, PHARMACEUTICAL AND BIOTECHNOLOGY PROGRAMS
Paradigm shifting development of health tech and the treatment of autoimmunity, chronic inflammation, infection, and cancer
HUB-AND-SPOKE BIOTECH DEVELOPMENT ENGINE POWERING EFFICEINT SMALL-SCALE MED-TECH, PHARMACEUTICAL AND BIOTECHNOLOGY PROGRAMS 2
Paradigm shifting development of health tech and the treatment of autoimmunity, chronic inflammation, infection, and cancer
Biostax Corp: A Biotech development engine powering efficient small-scale med-tech, pharmaceutical and biotechnology programs
CKD Treatment (Non-Binding LOI)
Currently negotiating terms for a late stage CKD treatment for the management of ESRD complicated by hyperphosphatemia. Terms may include license and/or commercial joint venture. Opportunity represents a potential partnership on future development with joint work on protocols and KOL development. We will provide a corporate update if and when negotiations progress beyond a non binding letter of intent. Please contact the company for more information under a required NDA.
Smart Contract EHR / Rx Program (Internal Program)
Internal program investigating the use of blockchain and distributed ledgers to provide enhanced security and control over electronic health records and prescriptions. This technology can offer exciting new ways for healthcare providers to access and augment medical research data, medical records and prescriptions. Smart contracts' immutable, encrypted nature can enhance patient privacy while allowing providers to adhere to regulations.
International HIV Program (Commercial)
Lodonal is currently approved in Nigeria for the treatment of HIV as a one-day Immune System Regulator for the management of HIV/AIDS. Trial conducted in Nigeria resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients and a reduction in opportunistic infections. Several Phase II multi-center, randomized studies demonstrated improvements for patients treated with Lodonal when compared to placebo or standard of care.
JKB-122 Program (License)
JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, and anti-inflammatory activities and improvement of liver injuries by hepatoprotectant property.
BiostaxRx (Internal Program)
BiostaxRx was founded on the principle that effective and affordable treatments now exist that address a large variety of chronic inflammatory diseases; and those that safely reduce inflammation without suppressing the immune system will take center stage in delivering a high quality of life to the greatest number of patients.
CKD Treatment (Non-Binding LOI)
Currently negotiating terms for a late stage CKD treatment for the management of ESRD complicated by hyperphosphatemia. Terms may include license and/or commercial joint venture. Opportunity represents a potential partnership on future development with joint work on protocols and KOL development. We will provide a corporate update if and when negotiations progress beyond a non binding letter of intent. Please contact the company for more information under a required NDA.
Smart Contract EHR / Rx Program (Internal Program)
Internal program investigating the use of blockchain and distributed ledgers to provide enhanced security and control over electronic health records and prescriptions. This technology can offer exciting new ways for healthcare providers to access and augment medical research data, medical records and prescriptions. Smart contracts' immutable, encrypted nature can enhance patient privacy while allowing providers to adhere to regulations.
International HIV Program (Commercial)
Lodonal is currently approved in Nigeria for the treatment of HIV as a one-day Immune System Regulator for the management of HIV/AIDS. Trial conducted in Nigeria resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients and a reduction in opportunistic infections. Several Phase II multi-center, randomized studies demonstrated improvements for patients treated with Lodonal when compared to placebo or standard of care.
JKB-122 Program (License)
JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, and anti-inflammatory activities and improvement of liver injuries by hepatoprotectant property.
CKD Treatment (Non-Binding LOI)
Currently negotiating terms for a late stage CKD treatment for the management of ESRD complicated by hyperphosphatemia. Terms may include license and/or commercial joint venture. Opportunity represents a potential partnership on future development with joint work on protocols and KOL development. We will provide a corporate update if and when negotiations progress beyond a non binding letter of intent. Please contact the company for more information under a required NDA.
Smart Contract EHR / Rx Program (Internal Program)
Internal program investigating the use of blockchain and distributed ledgers to provide enhanced security and control over electronic health records and prescriptions. This technology can offer exciting new ways for healthcare providers to access and augment medical research data, medical records and prescriptions. Smart contracts' immutable, encrypted nature can enhance patient privacy while allowing providers to adhere to regulations.
International HIV Program (Commercial)
Lodonal is currently approved in Nigeria for the treatment of HIV as a one-day Immune System Regulator for the management of HIV/AIDS. Trial conducted in Nigeria resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients and a reduction in opportunistic infections. Several Phase II multi-center, randomized studies that demonstrated improvements for patients treated with Lodonal when compared to placebo or standard of care.
JKB-122 Program (License)
JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, and anti-inflammatory activities and improvement of liver injuries by hepatoprotectant property.
BiostaxRx (Internal Program)
BiostaxRx was founded on the principle that effective and affordable treatments now exist that address a large variety of chronic inflammatory diseases; and those that safely reduce inflammation without suppressing the immune system will take center stage in delivering a high quality of life to the greatest number of patients.
CKD Treatment (Non-Binding LOI)
Currently negotiating terms for a late stage CKD treatment for the management of ESRD complicated by hyperphosphatemia. Terms may include license and/or commercial joint venture. Opportunity represents a potential partnership on future development with joint work on protocols and KOL development. We will provide a corporate update if and when negotiations progress beyond a non binding letter of intent. Please contact the company for more information under a required NDA.
Smart Contract EHR / Rx Program (Internal Program)
Internal program investigating the use of blockchain and distributed ledgers to provide enhanced security and control over electronic health records and prescriptions. This technology can offer exciting new ways for healthcare providers to access and augment medical research data, medical records and prescriptions. Smart contracts' immutable, encrypted nature can enhance patient privacy while allowing providers to adhere to regulations.
International HIV Program (Commercial)
Lodonal is currently approved in Nigeria for the treatment of HIV as a one-day Immune System Regulator for the management of HIV/AIDS. Trial conducted in Nigeria resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients and a reduction in opportunistic infections. Several Phase II multi-center, randomized studies that demonstrated improvements for patients treated with Lodonal when compared to placebo or standard of care.
JKB-122 Program (License)
JKB-122 is a small molecule and a long-acting TLR4 antagonist. This drug has demonstrated in preclinical models anti-fibrotic, immuno-modulating, and anti-inflammatory activities and improvement of liver injuries by hepatoprotectant property.
Lodonal ™
The Once-a-day Immune System-Regulator for the Management of HIV/AIDS
Lodonal™ is approved in Nigeria as a one-day Immune System Regulator for the management of HIV/AIDS, which is based on the results of the Company’s 90-Day bridging trial in Nigeria that resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients. Additionally, there was a reduction in opportunistic infections plus several Phase II multi-center, randomized studies that demonstrated improvements for patients treated with Lodonal™ when compared to placebo or standard of care.
Latest News
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception20231130144754
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception Orlando...
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception20231130144636
![]()
Orlando, FL, Nov. 30, 2023 — Biostax Corp., (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech developme...
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro20231115143241
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro Orlando, FL, November 15, 2023 (GLOBE NEWS...
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception20231130144754
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception Orlando...
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception20231130144636
Orlando, FL, Nov. 30, 2023 — Biostax Corp., (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech developme...
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro20231115143241
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro Orlando, FL, November 15, 2023 (GLOBE NEWS...
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors20231102141249
Orlando, FL, Nov. 02, 2023 — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development...
Sign Up for Email Alerts
Sign Up for Email Alerts
BiostaxRx Telehealth & Inflammaging Platform
BiostaxRx Telehealth & Inflammaging Platform: A World where Quality of Life Returns to Those with Inflammatory Disease
Worldwide 3 out of 5 people will die as a result of chronic inflammatory diseases.
Chronic inflammatory diseases are the most significant cause of death in the world. Without effective treatment, persons with autoimmunity & other chronic inflammatory conditions are denied a high quality of life.
Patients deserve better treatment options
Existing treatments are often toxic, immune suppressive or both. Because of harmful side effects, current therapeutics are used as sparingly as possible, often late in disease and largely treat symptoms: they are not curative.
BiostaxRx is shifting the paradigm
BiostaxRx was founded on the principle that effective and affordable treatments now exist that address a large variety of chronic inflammatory diseases; and those that safely reduce inflammation without suppressing the immune system will take center stage in delivering a high quality of life to the greatest number of patients.
